Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 222
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +25%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 551–553 of 553 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01911741	A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects	completed	Phase 1	55	Astellas Pharma Europe B.V.INDUSTRY	1	Jul 30, 2013	clinicaltrials
NCT01663415	A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer	withdrawn	Phase 2	0	Astellas Pharma Global Development, Inc.INDUSTRY	0	Sep 17, 2012